Company / Total Assets
Celldex Therapeutics, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$583.0M
FY2025
5-year range
$352.7M / $792.3M
FY2021-FY2025
Trend
-26.4%
vs FY2024
Sector context
#132 of 160
Health Care
What the data says
Celldex Therapeutics, Inc.'s total assets of $583M is lower than 82% of companies in the Health Care sector (FY2025). Total Assets has fluctuated over the past 10 years, ranging from $123M in FY2019 to $792M in FY2024.
Based on SEC 10-K filings.
$583M in FY2025 with a 5-year CAGR of +19.8%.
Improved from $466M to $583M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +18.2%
- 5-Year CAGR
- +19.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 160This company $583.0M Sector average $14.8B
▼
-96.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.8%, indicating consistent growth.
- In FY2025, total assets decreased 26.4% year-over-year.
- Ranks #132 out of 160 companies in the Health Care sector.
- Peak total assets was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $583.0M | -26.4% |
| FY2024 | $792.3M | +70.2% |
| FY2023 | $465.6M | +32.0% |
| FY2022 | $352.7M | -20.7% |
| FY2021 | $444.7M | +88.5% |
| FY2020 | $235.8M | +91.8% |
| FY2019 | $122.9M | -21.1% |
| FY2018 | $155.8M | -50.6% |
| FY2017 | $315.6M | -17.7% |
| FY2016 | $383.4M | +13.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026